# BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy

> **NIH NIH UM1** · WISTAR INSTITUTE · 2022 · $5,839,685

## Abstract

Summary
Current HIV curative strategies have proven insufficient to eradicate viral reservoirs or prevent viral rebound after
antiretroviral therapy (ART) cessation. The unifying hypothesis for the BEAT-HIV Collaboratory is that
through a better mechanistic understanding of HIV latent reservoirs and host factors governing viral
control and reactivation, long-term viral remission or eradication of HIV will be achieved by combination
immunotherapy inclusive of bNAbs, adoptively transferred immune cells, and nanoparticle therapies.
We will test this hypothesis by pursuing three highly interconnected research focus areas. The first aim will seek
to understand epigenetic status of intact proviruses, extrinsic/intrinsic factors affecting proviral reactivation and
expression, and novel host mechanisms for post-treatment control of HIV. The second aim will develop
strategies for long-term control in the absence of ART by use of DNA-delivered anti-HIV bNAbs and eCD4Ig in
combination with optimized tissue-based CD8 T-cell- and NK cell-mediated responses. The third aim will
develop a combination nanotherapy and immunotherapy strategy to eradicate viral reservoirs. All aims will be
supported by a clinical biorepository (blood and tissue), CD34+ or patient-derived xenograft humanized mice,
non-human primate (NHP) models, and a clinical trial development group as a link to the ACTG. Community
engagement will advance education and a socio-behavioral sciences and ethics focus by leveraging a >25-year
relationship with the local HIV community thereby ensuring partnership with stakeholders. Central administration
of resources will ensure achievement of high impact milestones, study team communications, and yearly goal-
oriented resource allocation and/or redistribution as informed by advances in the field. As an established
Collaboratory, we bring together diverse expertise, innovation, and industry partners to develop and test novel
strategies to advance an HIV cure and/or durable viral control in the absence of ART under a single common
multi-investigator, multi-industry team. Studies within the three interconnected aims together with a strong
community engagement plan will lay the groundwork for future clinical trials that will integrate new knowledge
gained by the BEAT HIV-1 Collaboratory to eradicate or functionally cure HIV infection.

## Key facts

- **NIH application ID:** 10469617
- **Project number:** 5UM1AI164570-02
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Luis J Montaner
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $5,839,685
- **Award type:** 5
- **Project period:** 2021-08-16 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10469617

## Citation

> US National Institutes of Health, RePORTER application 10469617, BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (5UM1AI164570-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10469617. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*